Structural Analysis of HIV-1 RNase H Bound to a Galloyl Active Site Inhibitor and Computational Compound Modification

Area of Science:

• Structural Biology
• Medicinal Chemistry
• Virology

Background:

• Drug-resistant human immunodeficiency virus type-1 (HIV-1) poses a significant treatment challenge.
• Targeting unexploited viral enzymes like RNase H can circumvent existing drug resistance.
• No approved inhibitors currently exist for HIV-1 RNase H activity.

Purpose of the Study:

• To determine the X-ray crystal structure of an HIV-1 RNase H domain bound to an inhibitor.
• To identify novel inhibitors of HIV-1 RNase H activity.
• To optimize inhibitor binding through molecular mechanics calculations.

Main Methods:

• X-ray crystallography of p15Ec (HIV-1 RNase H domain) with a pyrogallol-based inhibitor.
• Molecular mechanics (MM) calculations to assess binding scores and interactions.
• Computational generation and optimization of 6,757 pyrogallol derivatives.

Main Results:

• The crystal structure revealed pyrogallol moiety chelating two metal ions in the RNase H active site.
• MM calculations indicated the piperazine group was not essential for binding.
• Twelve novel galloyl derivatives demonstrated improved RNase H inhibitory activity.

Conclusions:

• The pyrogallol moiety is crucial for coordinating with metal ions in the RNase H active site.
• Optimized galloyl derivatives represent promising candidates for novel anti-HIV-1 therapies.
• This study provides a structural basis for developing new HIV-1 RNase H inhibitors.